[{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"COR-1167","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Exidavnemab","moa":"||Alpha-synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Neurotrope","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"||PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Worldwide Clinical Trials \/ Neurotrope","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Neurotrope"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"ImmuneOnco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IMM0306","moa":"||CD20\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"15","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"XEN1101","moa":"||Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"||Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"||Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"XEN1101","moa":"||Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Neurology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"9","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Lyndra Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Gate Neurosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zelquistinel","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cereno Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"||Succinate semialdehyde dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Worldwide Clinical Trials \/ Cybin","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Cybin"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cassava Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"||Filamin-A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Decitabine","moa":"||DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Edgewise Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sevasemten","moa":"||Myosin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Artelo Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"ART26.12","moa":"||FABP5","graph1":"Neurology","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ACI-24.060","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ACI-24.060","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"BioXcel Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BXCL501","moa":"||ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ketamine","moa":"||GABAA receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CYB003","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CYB003","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CYB003","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Kedrion","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Coagulation Factor X","moa":"||Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Inversago Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HT-001","moa":"||NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CYB004","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||WRN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketamine","moa":"||GABAA receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Worldwide Clinical Trials \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Worldwide Clinical Trials \/ Worldwide Clinical Trials"}]

Find Clinical Drug Pipeline Developments & Deals by Worldwide Clinical Trials

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Coagadex

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 08, 2025

                          Lead Product(s) : Coagulation Factor X,Inapplicable

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Recipient : Kedrion

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 27, 2025

                          Lead Product(s) : NDI-219216,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Nimbus Wadjet

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 07, 2025

                          Lead Product(s) : COR-1167,Inapplicable

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Recipient : Worldwide Clinical Trials

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 27, 2025

                          Lead Product(s) : CYB003,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Recipient : Cybin

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Tarpeyo

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          December 02, 2024

                          Lead Product(s) : Budesonide,Inapplicable

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase IV

                          Recipient : Calliditas Therapeutics AB

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 04, 2024

                          Lead Product(s) : Exidavnemab,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Recipient : BioArctic AB

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 20, 2024

                          Lead Product(s) : CYB003,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Recipient : Cybin

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 21, 2024

                          Lead Product(s) : CYB003,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Recipient : Cybin

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 09, 2024

                          Lead Product(s) : Zelquistinel,Inapplicable

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Recipient : Gate Neurosciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Under the partnership, Worldwide Clinical Trials will support the Phase 1 trial of ART26.12, a FABP5 inhibitor being developed for chemotherapy-induced peripheral neuropathy (CIPN).

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 01, 2024

                          Lead Product(s) : ART26.12,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Recipient : Artelo Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank